87942-08-3 Usage
General Description
4-N-PROPYLPHENYLMAGNESIjson BROMIDE is an organometallic compound with the chemical formula C9H13BrMg. It is commonly used as a reagent in organic synthesis, particularly for the Grignard reaction, where it acts as a source of the propyl phenylmagnesium nucleophile. 4-N-PROPYLPHENYLMAGNESIUM BROMIDE is an important tool in the production of various organic molecules, especially in the pharmaceutical and fine chemical industries. It is a highly reactive compound and should be handled with caution due to its flammability and potential for spontaneous ignition in air.
Check Digit Verification of cas no
The CAS Registry Mumber 87942-08-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,9,4 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 87942-08:
(7*8)+(6*7)+(5*9)+(4*4)+(3*2)+(2*0)+(1*8)=173
173 % 10 = 3
So 87942-08-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H11.BrH.Mg/c1-2-6-9-7-4-3-5-8-9;;/h4-5,7-8H,2,6H2,1H3;1H;/q;;+1/p-1/rC9H11BrMg/c1-2-3-8-4-6-9(11-10)7-5-8/h4-7H,2-3H2,1H3
87942-08-3Relevant articles and documents
Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
-
, (2008/06/13)
α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula STR1 wherein R2 is OR5 or R5a ; R3 and R5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.